Teclison

Teclison is a clinical-stage biotechnology company dedicated to developing innovative cancer therapies that induce tumor necrosis and enhance anti-tumor immunity. Teclison has developed a novel, first-in-class approach to enhance immune checkpoint inhibitor drugs, transforming the lives of cancer patients with solid tumors. Our Phase 2 compound, TEC-001, when used in combination with FDA-approved immune checkpoint inhibitors, induces significant tumor necrosis and long-term remission.